J
Joseph A. Caprini
Researcher at University of Chicago
Publications - 246
Citations - 14422
Joseph A. Caprini is an academic researcher from University of Chicago. The author has contributed to research in topics: Pulmonary embolism & Deep vein. The author has an hindex of 53, co-authored 238 publications receiving 12333 citations. Previous affiliations of Joseph A. Caprini include NorthShore University HealthSystem & Rush University Medical Center.
Papers
More filters
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Abstr Act,James D. Douketis,Alex C. Spyropoulos,Scott Kaatz,Richard C. Becker,Joseph A. Caprini,Andrew Dunn,David A. Garcia,Alan K. Jacobson,Amir K. Jaffer,David F. Kong,Sam Schulman,Thomas L. Ortel +12 more
TL;DR: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding.
Journal ArticleDOI
Thrombosis Risk Assessment as a Guide to Quality Patient Care
TL;DR: One of the most troubling statistics is the fact that 50% of he 2 million cases of DVT yearly are “silent,” Occasionally, the first ign or symptom of the disease is a fatal PE.
Journal ArticleDOI
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Jeffrey S. Ginsberg,Bruce L. Davidson,Charles W. Francis,Richard J. Friedman,Michael H. Huo,Jay R. Lieberman,James E. Muntz,Gary E. Raskob,Mary L Clements,Stefan Hantel,Janet Schnee,Joseph A. Caprini +11 more
TL;DR: Dabigatran, effective compared to once-daily enoxaparin, showed inferior efficacy to the twice-daily North American enoxAParin regimen, probably because of the latter's more intense and prolonged dosing.
Journal ArticleDOI
A validation study of a retrospective venous thromboembolism risk scoring method.
Vinita Bahl,Hsou Mei Hu,Peter K. Henke,Thomas W. Wakefield,Darrell A. Campbell,Joseph A. Caprini +5 more
TL;DR: The retrospective risk scoring method is valid and supports use of individual patient assessment of risk for VTE within 30 days after surgery, and significant correlation between the probability of VTE and lack of adherence to prophylaxis guidelines is demonstrated.